In this study, we aimed to evaluate dosimetric approaches in ablation treatment of Differentiated Thyroid Carcinoma (DTC) without interrupting the clinical routine. A strong correlation between 24th-hour uptake and time-integrated activity coefficient values was obtained. Compared to fixed activity method, approximately five times higher secondary cancer risk was determined in bone marrow dosimetry, while the risk was about three times lower in lesion-based dosimetry.
give maximum safe activity to patients. As stated in their study, they aimed to give maximum activity without exceeding 2 Gy dose to the blood as a surrogate for the bone marrow, the critical organ in RAI treatment. The second dosimetry technique is lesion-based dosimetry, which was first mentioned in the study of Maxon et al. in 1983 . 10 In their work, they suggested that minimum 300 Gy to the remnant thyroid tissue and minimum 80 Gy to metastases should be given for a successful treatment. The most important advantage of this method was to ablate the remnant tissue with lower activities.
This study aimed to determine the absorbed dose to bone marrow and remnant thyroid tissue of the patients with Differentiated
Thyroid Carcinoma before the ablation therapy without interrupting the clinical routine. The associated relative secondary cancer risk was also analyzed. 
| MATERIALS AND METHODS
To calculate the activity in the blood, 2 ml blood samples at 2, 24, 72, and 120 h were analyzed using the calibrated well-type NaI gamma counter (Capintec Captus-3000, Capintec, Inc. NJ, USA).
Anterior and posterior whole-body counts at 2, 24, 72, and 120 h were measured using the NaI probe detector (Capintec Captus-3000, Capintec, Inc. NJ, USA) at a distance of 2 m from the patient. The probe was positioned at the bottom level of the patient's sternum. 13 The position of the probe and the patient was constant for the counting repeatability.
Whole-body counts at 2 h were taken as a reference that represent the total administered activity because the patients were not allowed micturition until the measurements were performed. Position changes of the activity in the body were ignored.
The TIACs were calculated using the software solution NUK-FIT, 14 choosing the optimal fit functions as proposed by the code. A systematic error in activity determination of 10% was assumed in the calculations.
Another bone marrow dose calculation was performed according to the EANM bone marrow dosimetry guideline (EANM-2010). 15 For thyroid treatment with 131 I-NaI, only the dose from extracellular fluid to bone marrow and dose from the rest of the body to bone marrow were calculated as mentioned in the guideline. To estimate activity concentration in bone marrow based on activity concentration in blood, red marrow-to-blood activity concentration ratio (RMBLR) was used as unity. 15 S factor for the rest of the body was calculated according to EANM-2010. 15 Cristy and
Eckerman's 16 10-year-old child, adult female and male MIRD phantoms were used. S factors for bone marrow to bone marrow and whole-body to bone marrow were taken from the study by Stabin and Siegel. 17 
2.B | Remnant thyroid tissue dose calculation
For the calculation of dose to remnant thyroid tissue, the Unit-density Sphere Model was used. 18 In this model, the tissues were simulated as spheres with density of 1 g/cm 3 .
The remnant tissue volumes were determined using both Ultrasound (US) and planar gamma camera images taken at 24 h after 131 I intake. In US imaging, the diameters of the remnant tissue were measured in three dimensions. In the gamma camera imaging, a cylindrical source (having a diameter of 2. To calculate the cumulative activity in the thyroid, uptake values at 2, 24, 72, and 120 h after injection were determined using the thyroid uptake system. The time-activity curve of the thyroid was integrated using a trapezoidal integration. After the last time point, only the physical decay was taken into account.
The S factors for the remnant tissue dosimetry were determined from the fit function of the data by Stabin and Konijnenberg. 18 
2.C | Relative secondary cancer risk assessment in dosimetry approaches
Relative secondary cancer risk assessments in dosimetry approaches were done considering that doses to organs were directly proportional to the administered activity, and relative secondary cancer risk was directly proportional to the organ doses within the same patient.
Thus, relative secondary cancer risk in dosimetry approaches was determined by dividing activity calculated in the dosimetry approach by the applied treatment activity.
| RESULTS
All patients were in stage 1 according to TNM. 19 Blood and bone marrow doses according to the two different EANM guidelines are given in Table 2 . There was no significant difference observed between bone marrow doses according to two EANM guidelines (P > 0.05). Significant differences were found between blood and bone marrow doses from both guidelines (P < 0.05).
Effective half-life of the activity was determined as 12.9 h for the total body and 9.6 h for the blood. The corresponding TIAC values were 39.1 and 4.0 h, respectively.
As for thyroid remnant tissue, 24th-hour uptake, effective halflife (T ½ ), and TIAC values are shown in Table 3 .
Thyroid tissue volumes measured both with gamma camera and US and their related doses are indicated in Table 4 . The volume values were in a wide range between two modalities (average 4.6 cm 3 with gamma camera, while 1.4 cm 3 with US).
To be used in dosimetry calculations for future patients, the correlation between 24-h uptake and TIAC values was also investigated.
A strong correlation was obtained between these quantities (Adjusted R 2 = 0.972) (Fig. 1) .
Relative secondary cancer risk in selected dosimetry approaches with respect to the applied therapy is given in Although generally it is used for the patients with metastatic thyroid cancer, maximum safe activity calculation was also included in this study. The main reason for this is to be aware of the safe activity levels used in the treatments. Besides, not only blood doses for which Benua et al. 9 found a maximum safe absorbed dose of 2 Gy, but also bone marrow doses, for which an absorbed dose of 2 Gy is generally considered as safe, were calculated. 
The relationship between 24th-hour uptake value and TIAC.
The average blood dose was found as 0.15 Gy/GBq in this study.
Our result is compatible with the literature where the mean blood dose values are reported between 0.08 Gy/GBq and 0.23 Gy/ GBq. [21] [22] [23] [24] [25] Calculated maximum safe activities using both guidelines were much higher than the treatment activities decided by the fixed activity method. In other words, the bone marrow doses of the patients included in this study are much lower than the toxic dose for the bone marrow. Our findings also showed that bone marrow dosimetry is not an optimized approach for ablation treatment of thyroid cancer.
As for thyroid remnant tissue dosimetry, doses were calculated according to the tissue volumes obtained from not only gamma camera but also from US images. Remnant thyroid tissue doses based on gamma camera and US imaging measurement had an average value of 0.58 AE 0.52 and 2.91 AE 3.14 Gy/MBq, respectively ( Table 4) .
The difference as a factor of 5 between calculations was caused by the volume measurements of the remnant tissue. Determining the remnant volume with US or computed tomography (CT) is unreliable after surgery for ablation treatment. 8 The detection ability of the US imaging for small objects is limited. Thus, the remnant volumes determined by US images were considered as underestimating the remnant volume. The gamma camera volume estimation, however, was overestimating the remnant volume due to the spill-out effect.
Overestimating the volume leads to underestimation of the dose to remnant per unit activity. This approach gives additional safety margin for the therapies. Considering overestimated remnant thyroid tissue volume with gamma camera and 300 Gy to thyroid remnants is enough for the ablation as mentioned by Maxon et al., 10 approximately 1.3 GBq of 131 I in average should be sufficient for a successful ablation treatment. A strong correlation was obtained between TIAC and 24th-hour uptake values (Adjusted R 2 = 0.972) (Fig. 1) .
The correlation can be used for the estimation of TIAC values from single uptake measurement instead of a number of sequential measurements. This may increase patient comfort and prevent delays in therapy applications.
Relative secondary cancer risk assessments were performed with the assumptions stated in the Materials and Methods section.
According to this, risk is approximately four-and fivefold higher, respectively, in either blood or bone marrow dosimetry relative to the applied therapy. Our results also suggest that the risk can be reduced to approximately one third of the applied therapy by performing lesion-based dosimetry. As the survival rates after well-differentiated thyroid cancer are high, secondary cancer risk due to the radioiodine therapy is an important concern. For this reason, performing remnant tissue dosimetry for ablation treatment of thyroid cancer is strongly recommended.
| CONCLUSION
In the study, the dosimetry approaches in ablation treatment of welldifferentiated thyroid cancer were evaluated. It is shown that activities determined based on fixed activity treatment method can be safely given without reaching the toxic dose for bone marrow.
Administration of maximum safe activities according to the bone marrow dosimetry is not recommended for ablation treatment. On the other hand, with the lesion-based dosimetry, lower activities compared to fixed activity treatment method can be given to ablate the remnant tissue successfully. In addition to this, applying therapy according to lesion-based dosimetry with lower activities decrease the relative secondary cancer risk approximately three times. Large dose differences between patients show the necessity of patientspecific dosimetry.
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